Route: Gavage, IV

Species/Strain: Rat/F344

Toxicokinetics Data Summary

Test Compound: Pentachloroanisole

CAS Number: 1825-21-4

Date Report Requested: 12/29/2016 Time Report Requested: 14:39:06

Lab: NIEHS_Midwest Research Institute

Male

	Treatment Groups (mg/kg)					
	10 a, #	10 b, *	20 a, #	20 b, *	40 ^{a, #}	40 b, *
	Plasma					
C _{max} (ug/mL)	0.043 ± 0.002	29 ± 3	0.15 ± 0.035	66 ± 3	0.35 ± 0.069	107 ± 2
AUC _{0-t} (ug/mL/hr)	0.27 ± 0.01	542 ± 38	0.71 ± 0.27	988 ± 34	2.45 ± 0.73	1596 ± 59
F (percent)	14 ± 3	62 ± 4	19 ± 8	56 ± 2	31 ± 10	45 ± 2

Route: Gavage, IV

Species/Strain: Rat/F344

Toxicokinetics Data Summary

Test Compound: Pentachloroanisole

CAS Number: 1825-21-4

Date Report Requested: 12/29/2016 Time Report Requested: 14:39:06

Lab: NIEHS_Midwest Research Institute

Male

_	Treatment Groups (mg/kg)		
_	10 IV c, #	10 IV c, *	
	Plasma		
C _{max} (ug/mL)		32 ± 1	
AUC _{0-t} (ug/mL/hr)	1.93 ± 0.34	452 ± 13	
F (percent)			

Route: Gavage, IV

Species/Strain: Rat/F344

Toxicokinetics Data Summary

Test Compound: Pentachloroanisole

CAS Number: 1825-21-4

Date Report Requested: 12/29/2016 Time Report Requested: 14:39:06

Lab: NIEHS_Midwest Research Institute

Female	
--------	--

	Treatment Groups (mg/kg)					
	10 a, #	10 b, *	20 a, #	20 b, *	40 a, #	40 b, *
	Plasma					
C _{max} (ug/mL)	0.070 ± 0.010	44 ± 2	0.14 ± 0.020	80 ± 1	0.28 ± 0.14	136 ± 6
AUC _{0-t} (ug/mL/hr)	0.47 ± 0.075	704 ± 22	0.61 ± 0.10	1198 ± 36	3.00 ± 0.50	2084 ± 91
F (percent)	24 ± 8	96 ± 3	16 ± 5	82 ± 2	39 ± 14	71 ± 3

Route: Gavage, IV

Species/Strain: Rat/F344

Toxicokinetics Data Summary

Test Compound: Pentachloroanisole

CAS Number: 1825-21-4

Date Report Requested: 12/29/2016 Time Report Requested: 14:39:06

Lab: NIEHS_Midwest Research Institute

Female

_	Treatment Groups (mg/kg)		
_	10 IV c,#	10 IV c, *	
	Plasma		
C _{max} (ug/mL)		20 ± 3	
AUC _{0-t} (ug/mL/hr)	1.92 ± 0.62	385 ± 16	
F (percent)			

Route: Gavage, IV

Species/Strain: Rat/F344

Toxicokinetics Data Summary
Test Compound: Pentachloroanisole
CAS Number: 1825-21-4

Date Report Requested: 12/29/2016 Time Report Requested: 14:39:06 Lab: NIEHS_Midwest Research Institute

LEGEND

Data are displayed as mean ± SD

MODELING METHOD & BEST FIT MODEL

^a NONLIN; Open one-compartmental model. AUC estimated using the trapezoidal rule with an endpoint correction based on the estimated elimination half-life.

ANALYTE

- # Pentachloroanisole
- * Pentachlorophenol

TK PARAMETERS

C_{max} = Observed or Predicted Maximum plasma (or tissue) concentration

 $AUC_{0-t} = Area under the plasma concentration versus time curve, AUC, from time <math>t_i$ (initial) to t_f (final), AUC_{last}

F = Bioavailability, absolute bioavailability

** END OF REPORT **

^b NONLIN; Open one-compartmental model. AUC estimated using the trapezoidal rule with an endpoint correction based on the estimated elimination half-life. Bioavailability estimated by comparing AUC values obtained after intravenous administration of 5 mg/kg PCP versus AUC values of PCP after gavage administration of PCA.

^c NONLIN; Two-compartmental model with first-order elimination. AUC estimated using the trapezoidal rule with an endpoint correction based on the estimated elimination half-life.